Antitrust Trends in Technology, Life Sciences, and Healthcare

Healthcare remained a top priority for antitrust enforcers in the first half of 2026 as federal and state regulators remained active through a range of enforcement actions and policy initiatives.

The first half of 2026 brought a more permissive environment for technology M&A in the United States and a more mature, assertive phase of digital enforcement in Europe, against a backdrop of shifting legal frameworks, agency leadership changes, and procedural uncertainty.

The first half of 2026 featured a slew of significant M&A activity, regulatory developments abroad, and important jury verdicts in the life sciences space. As industry participants consider their next moves, it remains imperative to keep a close eye on the FTC in particular. The return of traditional antitrust enforcement principles has added a degree of predictability, but practitioners must still prepare for vigorous engagement on problematic transactions and those presenting novel issues or involving emerging therapeutic areas.

Visit our Antitrust & Competition page for details about how we help clients with merger clearance, complex litigation, as well as provide counsel on operational business issues.